Shachar Shlomit Strulov, Gallagher Kristalyn, McGuire Kandace, Zagar Timothy M, Faso Aimee, Muss Hyman B, Sweeting Raeshall, Anders Carey K
Department of Medicine, Division of Hematology-Oncology.
Lineberger Comprehensive Cancer Center.
Oncologist. 2017 Mar;22(3):324-334. doi: 10.1634/theoncologist.2016-0208. Epub 2017 Feb 23.
Although breast cancer during pregnancy (BCDP) is rare (occurring with only 0.4% of all BC diagnoses in female patients aged 16-49 years), management decisions are challenging to both the patient and the multidisciplinary team.
Experts in breast cancer at the University of North Carolina conducted a targeted literature search regarding the multidisciplinary treatment approaches to BCDP: medical, surgical, and radiation oncology. Supportive care, including antiemetic agents, and imaging approaches were also reviewed.
Review of the literature revealed key points in the management of BCDP. Surgical management is similar to that in nonpregnant patients; pregnant patients may safely undergo breast-conserving surgery. Recommendations should be tailored to the individual according to the clinical stage, tumor biology, genetic status, gestational age, and personal preferences. Anthracycline-based chemotherapy can be safely initiated only in the second and third trimesters. The rate of congenital abnormalities in children exposed to chemotherapy is similar to the national average (approximately 3%). Dosing of chemotherapy should be similar to that in the nonpregnant patient (i.e., actual body surface area). Antihuman epidermal growth factor receptor 2 therapy, radiation, and endocrine treatment are contraindicated in pregnancy and lactation. Care should include partnership with obstetricians. The literature regarding prognosis of BCDP is mixed.
To maximize benefit and minimize risk to the mother and fetus, an informed discussion with the patient and her medical team should result in an individualized treatment plan, taking into account the timing of the pregnancy and the stage and subtype of the breast cancer. Because BCDP is rare, it is essential to collect patient data in international registries. 2017;22:324-334 IMPLICATIONS FOR PRACTICE: Breast cancer during pregnancy is a major ethical and professional challenge for both the patient and the multidisciplinary treatment team. Although the oncologic care is based on that of the non-pregnant breast cancer patient, there are many challenges from regarding the medical, surgical and radiation oncology and obstetrical aspects of care that need to be considered to deliver the safest and best treatment plan to both the mother and developing fetus.
尽管孕期乳腺癌(BCDP)较为罕见(在16 - 49岁女性患者的所有乳腺癌诊断中仅占0.4%),但管理决策对患者和多学科团队而言都具有挑战性。
北卡罗来纳大学的乳腺癌专家针对BCDP的多学科治疗方法进行了有针对性的文献检索:包括医学、外科和放射肿瘤学。还对支持性护理(包括止吐药)及影像学方法进行了综述。
文献综述揭示了BCDP管理中的关键点。手术管理与非孕期患者相似;孕妇可安全地接受保乳手术。建议应根据临床分期、肿瘤生物学特性、基因状态、孕周和个人偏好进行个体化调整。基于蒽环类药物的化疗仅可在孕中期和孕晚期安全启动。接触化疗的儿童先天性异常发生率与全国平均水平相似(约3%)。化疗剂量应与非孕期患者相同(即根据实际体表面积)。抗人表皮生长因子受体2治疗、放疗和内分泌治疗在妊娠和哺乳期禁忌。护理应包括与产科医生合作。关于BCDP预后的文献结论不一。
为使母亲和胎儿的获益最大化并将风险最小化,与患者及其医疗团队进行充分沟通应能制定出个体化治疗方案,同时考虑妊娠时间以及乳腺癌的分期和亚型。由于BCDP罕见,在国际登记处收集患者数据至关重要。2017;22:324 - 334 对实践的启示:孕期乳腺癌对患者和多学科治疗团队而言都是重大的伦理和专业挑战。尽管肿瘤护理基于非孕期乳腺癌患者,但在医学、外科、放射肿瘤学及产科护理方面存在诸多挑战,需要加以考虑,以便为母亲和发育中的胎儿提供最安全、最佳的治疗方案。